0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV194.12%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma34.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cerus Stock Discussion
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
In Europe, the CE ...
Larger Image: tradingview.com...
$Cerus (CERS.US)$
Benzinga· 6 mins ago
Cerus Outlook FY Revenue USD 175-178 Million
No comment yet